Kyung Chan Park
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kyung Chan Park has a total of 152 co-authors. Here are the top co-authors by number of shared publications:
- Seon-Young Kim
Personalized Genomic Medicine Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Korea
51 shared publications - Byoung-Ha Yoon
Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea
50 shared publications - Cheolju Lee
Chemical and Biological Integrative Research Center, Korea Institute of Science and Technology, Seoul, Republic of Korea
49 shared publications - Geon Kook Lee
National Cancer Center, Goyang, Republic of Korea
49 shared publications - Jeong-Hwan Kim
Aging Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, Korea
49 shared publications - Ji-Youn Han
Center for Lung Cancer, National Cancer Center, Goyang, Republic of Korea
49 shared publications
Latest Publications
- Open Access
- 4 June 2026
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 11 (1) , 216
Transcriptional and epigenetic regulation of autophagy: mechanisms, disease relevance and therapeutic opportunities
Autophagy is a tightly regulated catabolic process that is essential for cellular homeostasis, stress adaptation, and metabolic balance. Its dysregulation has been implicated in a wide range of diseases, including cancer, neurodegenerative disorders, metabolic syndromes, muscular diseases, and infections. Recent studies have revealed the central roles of transcription factors, including TFEB, FOXO family members, p53, and NF-κB, in orchestrating autophagy through their direct regulation of lysosome-related genes. These factors often interact with epigenetic regulators such as histone acetyltransferases, deacetylases, and methyltransferases, which fine-tune chromatin accessibility and transcriptional output. Dysregulation of these pathways leads to aberrant autophagy and contributes to pathogenesis. Emerging therapeutic strategies targeting these transcriptional and epigenetic regulators have shown promise in preclinical and clinical settings, although challenges remain owing to the context-specific roles of autophagy in promoting either cell survival or cell death or contributing to protein aggregation and metabolic imbalance, depending on the disease. Clinical trials with autophagy modulators, including mTOR inhibitors, HDAC inhibitors, SIRT1 activators, and TFEB agonists, have yielded variable outcomes, emphasizing the need for precision medicine approaches. Advances in nanomedicine and biomaterials provide innovative delivery platforms that increase the specificity, bioavailability, and tissue targeting ability of autophagy-targeting agents. This review provides a comprehensive and detailed synthesis of how transcriptional and epigenetic regulators control autophagy across physiological and pathological contexts. In addition, we discuss therapeutic efforts, challenges in clinical translation, and future directions, including biomarker discovery, combinatorial treatment strategies, and targeted delivery systems, to enable more effective modulation of autophagy in disease.
- 4 June 2026
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 11 (1) , 216
Open AccessTranscriptional and epigenetic regulation of autophagy: mechanisms, disease relevance and therapeutic opportunities
Autophagy is a tightly regulated catabolic process that is essential for cellular homeostasis, stress adaptation, and metabolic balance. Its dysregulation has been implicated in a wide range of diseases, including cancer, neurodegenerative disorders, metabolic syndromes, muscular diseases, and infections. Recent studies have revealed the central roles of transcription factors, including TFEB, FOXO family members, p53, and NF-κB, in orchestrating autophagy through their direct regulation of lysosome-related genes. These factors often interact with epigenetic regulators such as histone acetyltransferases, deacetylases, and methyltransferases, which fine-tune chromatin accessibility and transcriptional output. Dysregulation of these pathways leads to aberrant autophagy and contributes to pathogenesis. Emerging therapeutic strategies targeting these transcriptional and epigenetic regulators have shown promise in preclinical and clinical settings, although challenges remain owing to the context-specific roles of autophagy in promoting either cell survival or cell death or contributing to protein aggregation and metabolic imbalance, depending on the disease. Clinical trials with autophagy modulators, including mTOR inhibitors, HDAC inhibitors, SIRT1 activators, and TFEB agonists, have yielded variable outcomes, emphasizing the need for precision medicine approaches. Advances in nanomedicine and biomaterials provide innovative delivery platforms that increase the specificity, bioavailability, and tissue targeting ability of autophagy-targeting agents. This review provides a comprehensive and detailed synthesis of how transcriptional and epigenetic regulators control autophagy across physiological and pathological contexts. In addition, we discuss therapeutic efforts, challenges in clinical translation, and future directions, including biomarker discovery, combinatorial treatment strategies, and targeted delivery systems, to enable more effective modulation of autophagy in disease.
- Open Access
- 29 November 2024
- Published by Springer Nature in Cancer Cell International
- Vol. 24 (1) , 1-20
CRHBP, a novel multiple cancer biomarker connected with better prognosis and anti-tumorigenicity
The corticotropin-releasing hormone-binding protein (CRHBP) plays a crucial role in regulating corticotropin release. Little is known about the role of CRHBP, a major regulator of neuroendocrine, autonomic, and stress adaptation, in tumors. In this study, we aimed to investigate the clinical and molecular landscapes of CRHBP in various types of tumors. We investigated the role of CRHBP in different types of tumors using publicly available databases and performed a comparative expression analysis of CRHBP-related genes in pan-cancer prognosis using methylation profiling, tumor-infiltrating immune cell expression analysis, gene enrichment analysis, and protein-protein interaction analysis, identified common pathways, and in vitro evaluation. We evaluated CRHBP expression across tumor and corresponding normal tissues using the data from The Cancer Genome Atlas and the Genotype-Tissue Expression database. CRHBP was downregulated in most tumors and was identified as an important factor for predicting the prognosis of patients with cancer. Intracellular metabolic pathways and hormone-related processes were involved in the functional mechanisms of CRHBP. Mechanistically, the downregulation of CRHBP was attributed to the upregulation of four miRNAs in most tumors, and CRHBP expression was related to tumor-infiltrating immune cells in tumors. Overexpression of CRHBP significantly inhibited cell proliferation of LUAD, LIHC, and KIRC cell lines, while inhibition of cell mobility was found only in KIRC and HCC cells. This study provides a comprehensive summary of the systemic role of CRHBP expression in various types of tumors, highlighting the prognostic importance and clinical significance of tumors. Furthermore, CRHBP decreases cell proliferation and mobility in cancer cell lines associated with OS and DFS, further research is needed to understand the underlying mechanisms and explore clinical applications.
- 29 November 2024
- Published by Springer Nature in Cancer Cell International
- Vol. 24 (1) , 1-20
Open AccessCRHBP, a novel multiple cancer biomarker connected with better prognosis and anti-tumorigenicity
The corticotropin-releasing hormone-binding protein (CRHBP) plays a crucial role in regulating corticotropin release. Little is known about the role of CRHBP, a major regulator of neuroendocrine, autonomic, and stress adaptation, in tumors. In this study, we aimed to investigate the clinical and molecular landscapes of CRHBP in various types of tumors. We investigated the role of CRHBP in different types of tumors using publicly available databases and performed a comparative expression analysis of CRHBP-related genes in pan-cancer prognosis using methylation profiling, tumor-infiltrating immune cell expression analysis, gene enrichment analysis, and protein-protein interaction analysis, identified common pathways, and in vitro evaluation. We evaluated CRHBP expression across tumor and corresponding normal tissues using the data from The Cancer Genome Atlas and the Genotype-Tissue Expression database. CRHBP was downregulated in most tumors and was identified as an important factor for predicting the prognosis of patients with cancer. Intracellular metabolic pathways and hormone-related processes were involved in the functional mechanisms of CRHBP. Mechanistically, the downregulation of CRHBP was attributed to the upregulation of four miRNAs in most tumors, and CRHBP expression was related to tumor-infiltrating immune cells in tumors. Overexpression of CRHBP significantly inhibited cell proliferation of LUAD, LIHC, and KIRC cell lines, while inhibition of cell mobility was found only in KIRC and HCC cells. This study provides a comprehensive summary of the systemic role of CRHBP expression in various types of tumors, highlighting the prognostic importance and clinical significance of tumors. Furthermore, CRHBP decreases cell proliferation and mobility in cancer cell lines associated with OS and DFS, further research is needed to understand the underlying mechanisms and explore clinical applications.
- Open Access
- 18 June 2024
- Published by Springer Nature in European Journal of Medical Research
- Vol. 29 (1) , 1-15
Role of SYT11 in human pan-cancer using comprehensive approaches
Synaptotagmin 11 (SYT11) plays a pivotal role in neuronal vesicular trafficking and exocytosis. However, no independent prognostic studies have focused on various cancers. In this study, we aimed to summarize the clinical significance and molecular landscape of SYT11 in various tumor types. Using several available public databases, we investigated abnormal SYT11 expression in different tumor types and its potential clinical association with prognosis, methylation profiling, immune infiltration, gene enrichment analysis, and protein–protein interaction analysis, and identified common pathways. TCGA and Genotype-Tissue Expression (GTEx) showed that SYT11 was widely expressed across tumor and corresponding normal tissues. Survival analysis showed that SYT11 expression correlated with the prognosis of seven cancer types. Additionally, SYT11 mRNA expression was not affected by promoter methylation, but regulated by certain miRNAs and associated with cancer patient prognosis. In vitro experiments further verified a negative correlation between the expression of SYT11 and miR-19a-3p in human colorectal, lung, and renal cancer cell lines. Moreover, aberrant SYT11 expression was significantly associated with immune infiltration. Pathway enrichment analysis revealed that the biological and molecular processes of SYT11 were related to clathrin-mediated endocytosis, Rho GTPase signaling, and cell motility-related functions. Our results provide a clear understanding of the role of SYT11 in various cancer types and suggest that SYT11 may be of prognostic and clinical significance.
- 18 June 2024
- Published by Springer Nature in European Journal of Medical Research
- Vol. 29 (1) , 1-15
Open AccessRole of SYT11 in human pan-cancer using comprehensive approaches
Synaptotagmin 11 (SYT11) plays a pivotal role in neuronal vesicular trafficking and exocytosis. However, no independent prognostic studies have focused on various cancers. In this study, we aimed to summarize the clinical significance and molecular landscape of SYT11 in various tumor types. Using several available public databases, we investigated abnormal SYT11 expression in different tumor types and its potential clinical association with prognosis, methylation profiling, immune infiltration, gene enrichment analysis, and protein–protein interaction analysis, and identified common pathways. TCGA and Genotype-Tissue Expression (GTEx) showed that SYT11 was widely expressed across tumor and corresponding normal tissues. Survival analysis showed that SYT11 expression correlated with the prognosis of seven cancer types. Additionally, SYT11 mRNA expression was not affected by promoter methylation, but regulated by certain miRNAs and associated with cancer patient prognosis. In vitro experiments further verified a negative correlation between the expression of SYT11 and miR-19a-3p in human colorectal, lung, and renal cancer cell lines. Moreover, aberrant SYT11 expression was significantly associated with immune infiltration. Pathway enrichment analysis revealed that the biological and molecular processes of SYT11 were related to clathrin-mediated endocytosis, Rho GTPase signaling, and cell motility-related functions. Our results provide a clear understanding of the role of SYT11 in various cancer types and suggest that SYT11 may be of prognostic and clinical significance.
- Open Access
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Proteogenomic Characterization Reveals Estrogen Signaling as a Target for Never-Smoker Lung Adenocarcinoma Patients without EGFR or ALK Alterations
Pathological review Tissue samples from surgically resected lung adenocarcinoma patients 1,597 Collected tissue samples 845 Excluded for
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Proteogenomic Characterization Reveals Estrogen Signaling as a Target for Never-Smoker Lung Adenocarcinoma Patients without EGFR or ALK Alterations
Pathological review Tissue samples from surgically resected lung adenocarcinoma patients 1,597 Collected tissue samples 845 Excluded for
- Open Access
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Table S6 from Proteogenomic Characterization Reveals Estrogen Signaling as a Target for Never-Smoker Lung Adenocarcinoma Patients without EGFR or ALK Alterations
Table S6 from Proteogenomic Characterization Reveals Estrogen Signaling as a Target for Never-Smoker Lung Adenocarcinoma Patients without EGFR or ALK Alterations
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from Proteogenomic Characterization Reveals Estrogen Signaling as a Target for Never-Smoker Lung Adenocarcinoma Patients without EGFR or ALK Alterations
Table S6 from Proteogenomic Characterization Reveals Estrogen Signaling as a Target for Never-Smoker Lung Adenocarcinoma Patients without EGFR or ALK Alterations
- Open Access
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Data from Proteogenomic Characterization Reveals Estrogen Signaling as a Target for Never-Smoker Lung Adenocarcinoma Patients without EGFR or ALK Alterations
Never-smoker lung adenocarcinoma (NSLA) is prevalent in Asian populations, particularly in women. EGFR mutations and anaplastic lymphoma kinase (ALK) fusions are major genetic alterations observed in NSLA, and NSLA with these alterations have been well studied and can be treated with targeted therapies. To provide insights into the molecular profile of NSLA without EGFR and ALK alterations (NENA), we selected 141 NSLA tissues and performed proteogenomic characterization, including whole genome sequencing (WGS), transcriptomic, methylation EPIC array, total proteomic, and phosphoproteomic analyses. Forty patients with NSLA harboring EGFR and ALK alterations and seven patients with NENA with microsatellite instability were excluded. Genome analysis revealed that TP53 (25%), KRAS (22%), and SETD2 (11%) mutations and ROS1 fusions (14%) were the most frequent genetic alterations in NENA patients. Proteogenomic impact analysis revealed that STK11 and ERBB2 somatic mutations had broad effects on cancer-associated genes in NENA. DNA copy number alteration analysis identified 22 prognostic proteins that influenced transcriptomic and proteomic changes. Gene set enrichment analysis revealed estrogen signaling as the key pathway activated in NENA. Increased estrogen signaling was associated with proteogenomic alterations, such as copy number deletions in chromosomes 14 and 21, STK11 mutation, and DNA hypomethylation of LLGL2 and ST14. Finally, saracatinib, an Src inhibitor, was identified as a potential drug for targeting activated estrogen signaling in NENA and was experimentally validated in vitro. Collectively, this study enhanced our understanding of NENA NSLA by elucidating the proteogenomic landscape and proposed saracatinib as a potential treatment for this patient population that lacks effective targeted therapies.Significance:The proteogenomic landscape in never-smoker lung cancer without known driver mutations reveals prognostic proteins and enhanced estrogen signaling that can be targeted as a potential therapeutic strategy to improve patient outcomes.
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Proteogenomic Characterization Reveals Estrogen Signaling as a Target for Never-Smoker Lung Adenocarcinoma Patients without EGFR or ALK Alterations
Never-smoker lung adenocarcinoma (NSLA) is prevalent in Asian populations, particularly in women. EGFR mutations and anaplastic lymphoma kinase (ALK) fusions are major genetic alterations observed in NSLA, and NSLA with these alterations have been well studied and can be treated with targeted therapies. To provide insights into the molecular profile of NSLA without EGFR and ALK alterations (NENA), we selected 141 NSLA tissues and performed proteogenomic characterization, including whole genome sequencing (WGS), transcriptomic, methylation EPIC array, total proteomic, and phosphoproteomic analyses. Forty patients with NSLA harboring EGFR and ALK alterations and seven patients with NENA with microsatellite instability were excluded. Genome analysis revealed that TP53 (25%), KRAS (22%), and SETD2 (11%) mutations and ROS1 fusions (14%) were the most frequent genetic alterations in NENA patients. Proteogenomic impact analysis revealed that STK11 and ERBB2 somatic mutations had broad effects on cancer-associated genes in NENA. DNA copy number alteration analysis identified 22 prognostic proteins that influenced transcriptomic and proteomic changes. Gene set enrichment analysis revealed estrogen signaling as the key pathway activated in NENA. Increased estrogen signaling was associated with proteogenomic alterations, such as copy number deletions in chromosomes 14 and 21, STK11 mutation, and DNA hypomethylation of LLGL2 and ST14. Finally, saracatinib, an Src inhibitor, was identified as a potential drug for targeting activated estrogen signaling in NENA and was experimentally validated in vitro. Collectively, this study enhanced our understanding of NENA NSLA by elucidating the proteogenomic landscape and proposed saracatinib as a potential treatment for this patient population that lacks effective targeted therapies.Significance:The proteogenomic landscape in never-smoker lung cancer without known driver mutations reveals prognostic proteins and enhanced estrogen signaling that can be targeted as a potential therapeutic strategy to improve patient outcomes.
- Open Access
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Table S11 from Proteogenomic Characterization Reveals Estrogen Signaling as a Target for Never-Smoker Lung Adenocarcinoma Patients without EGFR or ALK Alterations
Table S11 from Proteogenomic Characterization Reveals Estrogen Signaling as a Target for Never-Smoker Lung Adenocarcinoma Patients without EGFR or ALK Alterations
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S11 from Proteogenomic Characterization Reveals Estrogen Signaling as a Target for Never-Smoker Lung Adenocarcinoma Patients without EGFR or ALK Alterations
Table S11 from Proteogenomic Characterization Reveals Estrogen Signaling as a Target for Never-Smoker Lung Adenocarcinoma Patients without EGFR or ALK Alterations